These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36625758)

  • 21. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
    Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
    Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
    PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant-Free COVID-19 Vaccine with Glycoprotein Antigen Oxidized by Periodate Rapidly Elicits Potent Immune Responses.
    Zhang RY; Zhou SH; Feng RR; Wen Y; Ding D; Zhang ZM; Wei HW; Guo J
    ACS Chem Biol; 2023 Apr; 18(4):915-923. PubMed ID: 37009726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies.
    Aparicio B; Ruiz M; Casares N; Silva L; Egea J; Pérez P; Albericio G; Esteban M; García-Arriaza J; Lasarte JJ; Sarobe P
    Front Immunol; 2022; 13():1044025. PubMed ID: 36761163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
    Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
    Front Immunol; 2021; 12():729189. PubMed ID: 34603303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
    Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag.
    Yan W; Yu W; Shen L; Xiao L; Qi J; Hu T
    Int J Biol Macromol; 2023 Dec; 253(Pt 5):127159. PubMed ID: 37778577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
    Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants.
    Liu Y; Zhao D; Wang Y; Chen Z; Yang L; Li W; Gong Y; Gan C; Tang J; Zhang T; Tang D; Dong X; Yang Q; Valencia CA; Dai L; Qi S; Dong B; Chow HY; Li Y
    Front Immunol; 2022; 13():1011484. PubMed ID: 36439096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.
    Tabynov K; Solomadin M; Turebekov N; Babayeva M; Fomin G; Yadagiri G; Renu S; Yerubayev T; Petrovsky N; Renukaradhya GJ; Tabynov K
    Sci Rep; 2023 Jul; 13(1):12115. PubMed ID: 37495639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
    Lei Z; Zhu L; Pan P; Ruan Z; Gu Y; Xia X; Wang S; Ge W; Yao Y; Luo F; Xiao H; Guo J; Ding Q; Yin Z; Li Y; Luo Z; Zhang Q; Chen X; Wu J
    J Med Virol; 2023 Feb; 95(2):e28475. PubMed ID: 36606607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
    Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
    ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.
    Wang J; Yin XG; Wen Y; Lu J; Zhang RY; Zhou SH; Liao CM; Wei HW; Guo J
    J Med Chem; 2022 Feb; 65(4):3563-3574. PubMed ID: 35108485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
    Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
    Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. pGM-CSF as an adjuvant in DNA vaccination against SARS-CoV-2.
    Liu C; Xue RY; Li GC; Zhang Y; Wu WY; Liu JY; Feng R; Jin Z; Deng Y; Jin ZL; Cheng H; Mao L; Zou QM; Li HB
    Int J Biol Macromol; 2024 Apr; 264(Pt 2):130660. PubMed ID: 38460634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2.
    Huang H; Zhang C; Yang S; Xiao W; Zheng Q; Song X
    J Control Release; 2021 Jul; 335():449-456. PubMed ID: 34029632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
    Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
    Front Immunol; 2022; 13():974364. PubMed ID: 36159845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
    Zhang T; Wang Z; Yang J; Xu X
    J Med Virol; 2023 Feb; 95(2):e28563. PubMed ID: 36755368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.